Correlate of immune protection against HSV-1 genital disease in vaccinated women.
about
Understanding natural herpes simplex virus immunity to inform next-generation vaccine designThe herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects.Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging.Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein DBlocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral ImmunityHSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolatesAn HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysisDissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humansBovine herpesvirus glycoprotein D: a review of its structural characteristics and applications in vaccinologyHerpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.Evasion of early antiviral responses by herpes simplex viruses.The Current State of Vaccine Development for Ocular HSV-1 InfectionSeroprevalence of Herpes Simplex Virus Type 1 and 2 in Taiwan and Risk Factor Analysis, 2007.Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins.A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell ImmunogensPatient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract SheddingHerpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs.Future prospects for new vaccines against sexually transmitted infections.Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study.Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged ≥50 Years.Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection
P2860
Q26741484-F40B0056-25D1-4782-96E9-776F685A36DDQ33610941-3184AEF8-0713-4FFA-A229-BC8832FFE3A3Q33834821-C3EE076A-C283-45A4-AFAD-68430B006363Q33900262-38352C1B-6F23-4AA0-9318-1E0CC0F3CCF5Q34057952-8B6F0183-2682-438F-81EE-6695A7D9E6D5Q34229689-8EAF2757-2498-40DF-ADFB-1A8ED149B930Q34414463-BBB11CF2-5BB1-4A70-86E6-3F92EF023BE8Q34520389-3B0E6E17-CDBA-423C-BE84-5530F004C8C7Q34537743-A0C8963F-8743-4081-9AD4-EBCC152D2FEDQ34549656-021C62A5-D30D-4934-A120-E117922EDDB9Q34580831-C9147F34-2A5D-4CA5-9C8E-7E675DE872D9Q34593833-0E925705-46F9-4AD7-AFF3-7457E06D2E55Q34611897-10D32E14-2858-46CB-95E7-C3FC5391E93AQ35156674-DFD4B4DD-3D7A-4590-B739-F736F34DD14EQ35414669-BE8EAAEF-E659-4910-A598-773ED4E9DF6FQ35606611-89312AE6-F508-459B-924F-9EA1EC3BF052Q35739600-11B44DB8-4929-4C2B-9754-5203DAC1FA99Q35866976-36F05357-4FF7-429D-9777-54C1EB20F476Q35914319-E4BEFCA8-3E07-4FB9-BC95-1702F0F659D5Q35914367-9861EA38-F155-40EB-ADEA-8025D8DCCACAQ35973512-6D35C6AD-0222-4071-B073-3A28F7842325Q36080869-612B12F2-3BE3-40CD-BCC0-E354A5F99BE6Q36630996-EAB82F9E-4716-48C2-88F6-6FFAC05166D4Q36824210-90625A7A-CAC5-4CCA-BB42-5884CD9D7832Q36846035-E1D00857-2832-4938-A7F3-12EC31A4ABDAQ37531713-86E6C2C9-51F1-47CC-93F5-6A73495B30D8Q37665012-F25AFF20-DF53-4A8C-835D-768596AC6B12Q38241377-EF9E8CDC-38C4-492B-ABA3-B831043D532AQ38650844-17581A3A-A67A-4425-8FF8-C05D55CEB14EQ41928445-340CCB7F-A4F7-4BD2-8DD4-4C2FC2AC6A3CQ45324844-0A06C6C3-795B-484C-8A8D-9840F7EBBEB0Q47184537-283FCB4C-7219-4D66-B710-A6C5E52FF51EQ52727148-09EEBD2D-E084-4563-9D02-C5086802C14DQ55406946-E404E96D-50F9-41C8-B6CF-1506FCA492F9Q57072187-E6AB0BD5-2A50-49FE-BA22-7FADC635D9E6
P2860
Correlate of immune protection against HSV-1 genital disease in vaccinated women.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Correlate of immune protection against HSV-1 genital disease in vaccinated women.
@en
Correlate of immune protection against HSV-1 genital disease in vaccinated women.
@nl
type
label
Correlate of immune protection against HSV-1 genital disease in vaccinated women.
@en
Correlate of immune protection against HSV-1 genital disease in vaccinated women.
@nl
prefLabel
Correlate of immune protection against HSV-1 genital disease in vaccinated women.
@en
Correlate of immune protection against HSV-1 genital disease in vaccinated women.
@nl
P2093
P2860
P356
P1476
Correlate of immune protection against HSV-1 genital disease in vaccinated women.
@en
P2093
Abbie R Bellamy
Carolyn D Deal
David I Bernstein
Marian Ewell
Robbert van der Most
Robert B Belshe
Thomas C Heineman
P2860
P304
P356
10.1093/INFDIS/JIT651
P407
P577
2013-11-27T00:00:00Z